Deerfield Management Company, L.P. (Series C) Kinnate Biopharma Inc. Transaction History

Deerfield Management Company, L.P. (Series C)

$5.38 Billion
Q3 2024

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$7.43 - $13.0 $5.47 Million - $9.56 Million	-735,568 Reduced 74.63%	250,000 $3.15 Million
Q4 2021 Feb 14, 2022	SELL	$16.5 - $25.48 $708,510 - $1.09 Million	-42,940 Reduced 4.17%	985,568 $17.5 Million
Q3 2021 Nov 15, 2021	BUY	$17.81 - $24.87 $151,527 - $211,593	8,508 Added 0.83%	1,028,508 $23.7 Million
Q2 2021 Aug 16, 2021	BUY	$22.19 - $31.55 $15 Million - $21.3 Million	675,000 Added 195.65%	1,020,000 $23.7 Million
Q4 2020 Feb 16, 2021	BUY	$36.35 - $45.25 $12.5 Million - $15.6 Million	345,000 New	345,000 $13.7 Million

Others Institutions Holding KNTE

# of Institutions

Shares Held

292K

Call Options Held

Put Options Held

Foresite Capital Opportunity Management V, LLC Larkspur, CA

292K
Shares

$0
10.46% of portfolio
Wipfli Financial Advisors Llc,

109
Shares

$0
0.0% of portfolio

View Full List

About Kinnate Biopharma Inc.

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

More about KNTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Account